Squarepoint Ops LLC Ovid Therapeutics Inc. Transaction History

Squarepoint Ops LLC

  • $62.8 Billion
  • Q3 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$2.72 - $4.04 $154,936 - $230,126
56,962 Added 500.5%
68,343 $208,000
Q4 2023

Feb 14, 2024
BUY
$2.98 - $3.78 $33,915 - $43,020
11,381 New
11,381 $36,000
Q1 2023

May 15, 2023
BUY
$1.88 - $2.85 $21,189 - $32,122
11,271 New
11,271 $29,000
Q2 2022

Aug 15, 2022
BUY
$1.69 - $3.31 $17,817 - $34,897
10,543 New
10,543 $23,000
Q3 2021

Nov 15, 2021
SELL
$3.31 - $4.04 $125,108 - $152,699
-37,797 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$3.3 - $4.49 $124,730 - $169,708
37,797 New
37,797 $148,000
Q1 2021

May 17, 2021
SELL
$2.42 - $4.47 $171,788 - $317,311
-70,987 Closed
0 $0
Q4 2020

Feb 16, 2021
SELL
$2.28 - $6.84 $158,986 - $476,960
-69,731 Reduced 49.55%
70,987 $164,000
Q3 2020

Nov 16, 2020
BUY
$5.39 - $8.24 $758,470 - $1.16 Million
140,718 New
140,718 $808,000
Q2 2020

Aug 14, 2020
SELL
$2.67 - $7.91 $30,846 - $91,384
-11,553 Closed
0 $0
Q1 2020

May 15, 2020
SELL
$2.03 - $4.35 $29,386 - $62,970
-14,476 Reduced 55.61%
11,553 $34,000
Q4 2019

Feb 14, 2020
BUY
$2.08 - $5.06 $54,140 - $131,706
26,029 New
26,029 $108,000
Q3 2018

Nov 14, 2018
SELL
$5.6 - $11.0 $82,320 - $161,700
-14,700 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$6.16 - $10.14 $90,552 - $149,058
14,700 New
14,700 $115,000

Others Institutions Holding OVID

# of Institutions
75
Shares Held
39M
Call Options Held
37.4K
Put Options Held
500
View Full List

About Ovid Therapeutics Inc.

OVID Quotes by TradingView
  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $73.2M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email